Top News

Here’s what to know about PMOS, or polyendocrine metabolic ovarian syndrome.

Reviewed by Dietitian Jessica Ball, M.S., RD

Key Points

• PCOS has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to reflect its complexity.
• PMOS impacts hormones, metabolism and mental health, going beyond reproductive symptoms.
• The name change aims to improve care, diagnosis and research for millions worldwide by 2028.

For decades, millions of people have navigated a complex health condition known as polycystic ovary syndrome, or PCOS. It affects roughly one in eight women worldwide, bringing a range of potential symptoms that impact weight, mental health, skin and the reproductive system. But the medical community recently made a major update: PCOS has officially been renamed to polyendocrine metabolic ovarian syndrome (PMOS).

The shift goes far beyond a simple rebrand. It corrects a longstanding misunderstanding about how the condition actually works and demands that healthcare systems treat it with the seriousness it deserves. Here’s what to know about the change.

Why Change the Name?

For too long, the name PCOS reduced a whole-body hormonal issue to a narrow focus on the ovaries. The word “polycystic” led many people—and even some doctors—to mistakenly believe that abnormal ovarian cysts were the root cause of the disorder.

Research shows there is no increase in abnormal cysts on the ovary in people with this condition. The follicles seen on ultrasounds are a result of the condition, not the cause, and the misnomer contributed to widespread confusion. Patients often felt misunderstood, and the narrow reproductive focus caused delayed diagnoses and inadequate care for the broader symptoms they experienced.

What Is PMOS?

PMOS is a complex polyendocrine and metabolic condition. This means it involves multiple interacting hormones and affects the body’s entire metabolic system.

Insulin resistance affects a majority of individuals with the condition. This metabolic imbalance can drive excessive hormone production, which disrupts the entire system. Because of this, the features of PMOS span far beyond reproductive health. People with the condition often face metabolic challenges, such as higher risks for type 2 diabetes and cardiovascular issues. They’re also likely to experience dermatological symptoms like acne or hair loss, alongside psychological impacts including anxiety and depression.

The new name accurately captures this multisystem reality, explicitly recognizing the endocrine and metabolic factors at play.

How Was the Name Changed?

Changing a medical name is a massive undertaking. In fact, this new name is the result of 14 years of global collaboration. Experts, health professionals and people with lived experience worked together to find a medically accurate term. The initiative involved more than 50 patient and professional organizations and gathered more than 22,000 survey responses. The researchers who worked on the project shared more about the process in an announcement in The Lancet.

“It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition,” Helena Teede, MBBS, Ph.D.an endocrinologist who played a role in the name change process and has spent decades researching the condition and seeing the impacts firsthand, shared in a press release.

Teede also noted that while PMOS treatment has improved over the years, an official name change was “critical” to improving diagnosis and care going forward.

“This change was driven with and for those affected by the condition, and we are proud to have arrived at a new name that finally accurately reflects the complexity of the condition,” Teede added. “Make no mistake, this is a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research.”

Patients played a central role in driving this change. Experts noted that the old name misrepresented the true nature of the condition. The hope is that leading with the hormonal and metabolic dimensions will reframe the conversation, ensuring doctors and researchers take the condition seriously.

The medical community will phase in the PMOS name over a three-year transition period. This shift is supported by an international education campaign aimed at doctors, researchers, and governments. By 2028, the new name will be fully integrated into international clinical guidelines.

Our Expert Take

Ultimately, updating the condition’s name to polyendocrine metabolic ovarian syndrome (PMOS) will hopefully clear the path for better clinical care, more focused research funding and an improved experience for millions of people who are living with this syndrome worldwide. Experts project that the name change will be widely reflected by 2028, so don’t be surprised if you continue to see both acronyms used interchangeably for a year or so.